Circulating immunoreactive interleukin-6 in cystic fibrosis

被引:114
作者
Nixon, LS [1 ]
Yung, B [1 ]
Bell, SC [1 ]
Elborn, JS [1 ]
Shale, DJ [1 ]
机构
[1] Univ Wales, Coll Med, Sect Resp Med, UWCM Acad Ctr,Llandough Hosp NHS Trust, Penarth CF64 2XX, S Glam, Wales
关键词
D O I
10.1164/ajrccm.157.6.9704086
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
We measured circulating and sputum-sol concentrations of interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), neutrophil elastase-alpha(1)-antiproteinase complex (NEAPC), and C-reactive protein (CRP) in an exacerbation, after antibiotic treatment, and in clinically stable patients with cystic fibrosis and chronic pulmonary infection with Pseudomonas aeruginosa. The aim was to determine the compartmental patterns of a proinflammatory and anti-inflammatory cytokine compared with other markers of inflammatory activity in cystic fibrosis. IL-6, NEAPC, CRP, and absolute neutrophil count were reduced after antibiotic treatment, p < 0.01. IL-6 and CRP concentrations were greater, p = 0.007, and p = 0.01, respectively, in a stable group of patients compared with those at the end of an exacerbation. IL-6 and CRP concentrations were related (r = 0.836, p < 0.0001), and both were greater than in matched control subjects (p < 0.001) at all times studied. Sputum-sol concentrations of IL-6 after treatment were positively related to FEV1 and FVC and inversely related to concentrations of neutrophil elastase. The separation between patients and healthy subjects, and the reduction of IL-6 after antibiotic treatment indicates it could be used as a marker of inflammation, but its relationship to other markers depends on the compartment in which it is measured.
引用
收藏
页码:1764 / 1769
页数:6
相关论文
共 35 条
[1]  
ADERKA D, 1989, J IMMUNOL, V143, P3517
[2]   IL-6 AND NF-IL6 IN ACUTE-PHASE RESPONSE AND VIRAL-INFECTION [J].
AKIRA, S ;
KISHIMOTO, T .
IMMUNOLOGICAL REVIEWS, 1992, 127 :25-50
[3]   NORMAL BRONCHIAL EPITHELIAL-CELLS CONSTITUTIVELY PRODUCE THE ANTIINFLAMMATORY CYTOKINE INTERLEUKIN-10, WHICH IS DOWN-REGULATED IN CYSTIC-FIBROSIS [J].
BONFIELD, TL ;
KONSTAN, MW ;
BURFEIND, P ;
PANUSKA, JR ;
HILLIARD, JB ;
BERGER, M .
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 1995, 13 (03) :257-261
[4]  
BORDEN EC, 1994, J LAB CLIN MED, V123, P824
[5]   CIRCULATING LEVELS OF TUMOR-NECROSIS-FACTOR AND INTERLEUKIN-1 IN CYSTIC-FIBROSIS [J].
BROWN, MA ;
MORGAN, WJ ;
FINLEY, PR ;
SCUDERI, P .
PEDIATRIC PULMONOLOGY, 1991, 10 (02) :86-91
[6]   INTERLEUKIN-6, GAMMA-INTERFERON, AND TUMOR-NECROSIS-FACTOR RECEPTORS IN TYPHOID-FEVER RELATED TO OUTCOME OF ANTIMICROBIAL THERAPY [J].
BUTLER, T ;
HO, M ;
ACHARYA, G ;
TIWARI, M ;
GALLATI, H .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (11) :2418-2421
[7]  
COHICK CB, 1994, J LAB CLIN MED, V123, P721
[8]   A COMPARISON OF SURVIVAL, GROWTH, AND PULMONARY-FUNCTION IN PATIENTS WITH CYSTIC-FIBROSIS IN BOSTON AND TORONTO [J].
COREY, M ;
MCLAUGHLIN, FJ ;
WILLIAMS, M ;
LEVISON, H .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1988, 41 (06) :583-591
[9]  
DEMBIC Z, 1990, Cytokine, V2, P231, DOI 10.1016/1043-4666(90)90022-L
[10]   TUMOR-NECROSIS-FACTOR-ALPHA, RESTING ENERGY-EXPENDITURE AND CACHEXIA IN CYSTIC-FIBROSIS [J].
ELBORN, JS ;
CORDON, SM ;
WESTERN, PJ ;
MACDONALD, IA ;
SHALE, DJ .
CLINICAL SCIENCE, 1993, 85 (05) :563-568